Search

Your search keyword '"Kamikawaji, Shogo"' showing total 10 results
Start Over Author "Kamikawaji, Shogo"
10 results on '"Kamikawaji, Shogo"'

1. Supplementary Methods from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer

Author

Mikami, Hirofumi, primary, Feng, Shu, primary, Matsuda, Yutaka, primary, Ishii, Shinya, primary, Naoi, Sotaro, primary, Azuma, Yumiko, primary, Nagano, Hiroaki, primary, Asanuma, Kentaro, primary, Kayukawa, Yoko, primary, Tsunenari, Toshiaki, primary, Kamikawaji, Shogo, primary, Iwabuchi, Ryutaro, primary, Shinozuka, Junko, primary, Yamazaki, Masaki, primary, Kuroi, Haruka, primary, Ho, Samantha Shu Wen, primary, Gan, Siok Wan, primary, Chichili, Priyanka, primary, Pang, Chai Ling, primary, Yeo, Chiew Ying, primary, Shimizu, Shun, primary, Hironiwa, Naoka, primary, Kinoshita, Yasuko, primary, Shimizu, Yuichiro, primary, Sakamoto, Akihisa, primary, Muraoka, Masaru, primary, Takahashi, Noriyuki, primary, Kawa, Tatsuya, primary, Shiraiwa, Hirotake, primary, Mimoto, Futa, primary, Kashima, Kenji, primary, Kamata-Sakurai, Mika, primary, Ishikawa, Shumpei, primary, Aburatani, Hiroyuki, primary, Kitazawa, Takehisa, primary, and Igawa, Tomoyuki, primary

Published
2024
Full Text
View/download PDF

2. Table S1 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer

Author

Mikami, Hirofumi, primary, Feng, Shu, primary, Matsuda, Yutaka, primary, Ishii, Shinya, primary, Naoi, Sotaro, primary, Azuma, Yumiko, primary, Nagano, Hiroaki, primary, Asanuma, Kentaro, primary, Kayukawa, Yoko, primary, Tsunenari, Toshiaki, primary, Kamikawaji, Shogo, primary, Iwabuchi, Ryutaro, primary, Shinozuka, Junko, primary, Yamazaki, Masaki, primary, Kuroi, Haruka, primary, Ho, Samantha Shu Wen, primary, Gan, Siok Wan, primary, Chichili, Priyanka, primary, Pang, Chai Ling, primary, Yeo, Chiew Ying, primary, Shimizu, Shun, primary, Hironiwa, Naoka, primary, Kinoshita, Yasuko, primary, Shimizu, Yuichiro, primary, Sakamoto, Akihisa, primary, Muraoka, Masaru, primary, Takahashi, Noriyuki, primary, Kawa, Tatsuya, primary, Shiraiwa, Hirotake, primary, Mimoto, Futa, primary, Kashima, Kenji, primary, Kamata-Sakurai, Mika, primary, Ishikawa, Shumpei, primary, Aburatani, Hiroyuki, primary, Kitazawa, Takehisa, primary, and Igawa, Tomoyuki, primary

Published
2024
Full Text
View/download PDF

3. Figure S4 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer

Author

Mikami, Hirofumi, primary, Feng, Shu, primary, Matsuda, Yutaka, primary, Ishii, Shinya, primary, Naoi, Sotaro, primary, Azuma, Yumiko, primary, Nagano, Hiroaki, primary, Asanuma, Kentaro, primary, Kayukawa, Yoko, primary, Tsunenari, Toshiaki, primary, Kamikawaji, Shogo, primary, Iwabuchi, Ryutaro, primary, Shinozuka, Junko, primary, Yamazaki, Masaki, primary, Kuroi, Haruka, primary, Ho, Samantha Shu Wen, primary, Gan, Siok Wan, primary, Chichili, Priyanka, primary, Pang, Chai Ling, primary, Yeo, Chiew Ying, primary, Shimizu, Shun, primary, Hironiwa, Naoka, primary, Kinoshita, Yasuko, primary, Shimizu, Yuichiro, primary, Sakamoto, Akihisa, primary, Muraoka, Masaru, primary, Takahashi, Noriyuki, primary, Kawa, Tatsuya, primary, Shiraiwa, Hirotake, primary, Mimoto, Futa, primary, Kashima, Kenji, primary, Kamata-Sakurai, Mika, primary, Ishikawa, Shumpei, primary, Aburatani, Hiroyuki, primary, Kitazawa, Takehisa, primary, and Igawa, Tomoyuki, primary

Published
2024
Full Text
View/download PDF

4. Data from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer

Author

Mikami, Hirofumi, primary, Feng, Shu, primary, Matsuda, Yutaka, primary, Ishii, Shinya, primary, Naoi, Sotaro, primary, Azuma, Yumiko, primary, Nagano, Hiroaki, primary, Asanuma, Kentaro, primary, Kayukawa, Yoko, primary, Tsunenari, Toshiaki, primary, Kamikawaji, Shogo, primary, Iwabuchi, Ryutaro, primary, Shinozuka, Junko, primary, Yamazaki, Masaki, primary, Kuroi, Haruka, primary, Ho, Samantha Shu Wen, primary, Gan, Siok Wan, primary, Chichili, Priyanka, primary, Pang, Chai Ling, primary, Yeo, Chiew Ying, primary, Shimizu, Shun, primary, Hironiwa, Naoka, primary, Kinoshita, Yasuko, primary, Shimizu, Yuichiro, primary, Sakamoto, Akihisa, primary, Muraoka, Masaru, primary, Takahashi, Noriyuki, primary, Kawa, Tatsuya, primary, Shiraiwa, Hirotake, primary, Mimoto, Futa, primary, Kashima, Kenji, primary, Kamata-Sakurai, Mika, primary, Ishikawa, Shumpei, primary, Aburatani, Hiroyuki, primary, Kitazawa, Takehisa, primary, and Igawa, Tomoyuki, primary

Published
2024
Full Text
View/download PDF

6. Abstract 1872: A DLL3/CD3/CD137 trispecific T cell engager shows potent antitumor activity in small cell lung cancer models

Author

Mikami, Hirofumi, primary, Feng, Shu, additional, Naoi, Sotaro, additional, Azuma, Yumiko, additional, Kayukawa, Yoko, additional, Tsunenari, Toshiaki, additional, Asanuma, Kentaro, additional, Iwabuchi, Ryutaro, additional, Nagano, Hiroaki, additional, Shinozuka, Junko, additional, Yamazaki, Masaki, additional, Kuroi, Haruka, additional, Gan, Siok Wan, additional, Chichili, Priyanka, additional, Shimizu, Shun, additional, Matsuda, Yutaka, additional, Ishii, Shinya, additional, Kamikawaji, Shogo, additional, Kinoshita, Yasuko, additional, Shimizu, Yuichiro, additional, Sakamoto, Akihisa, additional, Muraoka, Masaru, additional, Takahashi, Noriyuki, additional, Kawa, Tatsuya, additional, Shiraiwa, Hirotake, additional, Kashima, Kenji, additional, Mimoto, Futa, additional, Kamata-Sakurai, Mika, additional, Kitazawa, Takehisa, additional, and Igawa, Tomoyuki, additional

Published
2023
Full Text
View/download PDF

7. Identification of the autophosphorylation sites of LRRK2

Author

Kamikawaji, Shogo, Ito, Genta, and Iwatsubo, Takeshi

Subjects
Leucine -- Chemical properties, Phosphorylation -- Analysis, Phosphotransferases -- Chemical properties, Proteins -- Structure, Proteins -- Analysis, Biological sciences, Chemistry
Abstract

Several studies are conducted for the identification of the various carboxyl-half fragments of LRRK2 (leucine-rich repeat kinase 2) that are shown to act as the autophosphorylation sites. The various mechanisms involved in the occurrence of autophosphorylation in holoproteins are explained.

Published
2009

10. Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer.

Author

Mikami H, Feng S, Matsuda Y, Ishii S, Naoi S, Azuma Y, Nagano H, Asanuma K, Kayukawa Y, Tsunenari T, Kamikawaji S, Iwabuchi R, Shinozuka J, Yamazaki M, Kuroi H, Ho SSW, Gan SW, Chichili P, Pang CL, Yeo CY, Shimizu S, Hironiwa N, Kinoshita Y, Shimizu Y, Sakamoto A, Muraoka M, Takahashi N, Kawa T, Shiraiwa H, Mimoto F, Kashima K, Kamata-Sakurai M, Ishikawa S, Aburatani H, Kitazawa T, and Igawa T

Subjects
Humans, Animals, Mice, Antibodies, Bispecific pharmacology, Antibodies, Bispecific therapeutic use, Cell Line, Tumor, Lymphocyte Activation immunology, Female, Lymphocytes, Tumor-Infiltrating immunology, Lymphocytes, Tumor-Infiltrating metabolism, Xenograft Model Antitumor Assays, Small Cell Lung Carcinoma immunology, Small Cell Lung Carcinoma pathology, Small Cell Lung Carcinoma drug therapy, Small Cell Lung Carcinoma therapy, Small Cell Lung Carcinoma metabolism, Lung Neoplasms immunology, Lung Neoplasms pathology, Lung Neoplasms drug therapy, Tumor Necrosis Factor Receptor Superfamily, Member 9 metabolism, CD3 Complex immunology, T-Lymphocytes immunology, T-Lymphocytes metabolism, Intracellular Signaling Peptides and Proteins metabolism, Membrane Proteins metabolism, Membrane Proteins immunology
Abstract

Small-cell lung cancer (SCLC) is an aggressive cancer for which immune checkpoint inhibitors (ICI) have had only limited success. Bispecific T-cell engagers are promising therapeutic alternatives for ICI-resistant tumors, but not all patients with SCLC are responsive. Herein, to integrate CD137 costimulatory function into a T-cell engager format and thereby augment therapeutic efficacy, we generated a CD3/CD137 dual-specific Fab and engineered a DLL3-targeted trispecific antibody (DLL3 trispecific). The CD3/CD137 dual-specific Fab was generated to competitively bind to CD3 and CD137 to prevent DLL3-independent cross-linking of CD3 and CD137, which could lead to systemic T-cell activation. We demonstrated that DLL3 trispecific induced better tumor growth control and a marked increase in the number of intratumoral T cells compared with a conventional DLL3-targeted bispecific T-cell engager. These findings suggest that DLL3 trispecific can exert potent efficacy by inducing concurrent CD137 costimulation and provide a promising therapeutic option for SCLC., (©2024 American Association for Cancer Research.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results